Terms & Conditions INTRODUCTION These terms and conditions govern your use of this website. These terms and conditions of use are entered into by and between You and the Neuroendocrine Cancer Foundation (“Neuroendocrine Cancer Foundation” “I,” “we,” “us” and “our”). The following terms and conditions of use, together with any documents expressly incorporated by reference (collectively, these “Terms of Use”) govern your access to and use of the Website, its Content, its Social Media and our Apps. By using this website, you agree to be bound by and accept these terms and conditions in full. If you disagree with these terms and conditions or any part of these terms and conditions, you must not use this website. 1. THIS SITE DOES NOT PROVIDE MEDICAL ADVICE General The information contained on the www.neuroendocrinecancer.net website is for general information purposes only. The Neuroendocrine Cancer Foundation assumes no responsibility for errors or omissions in the contents on the Service. In no event shall Neuroendocrine Cancer Foundation be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Neuroendocrine Cancer Foundation reserves the right to make additions, deletions, or modifications to the contents on the Service at any time without prior notice. Informational & Educational Purposes Only The Neuroendocrine Cancer Foundation does not warrant that the website is free of viruses or other harmful components. The Site, Content and/or Services are intended for informational & educational purposes only and are not intended as professional medical advice. By accessing and using the Site and/or Services, such use shall constitute your agreement that the Site and/or Services is not professional medical advice and shall not be relied upon by you as such. Nothing in the content, products or services should be considered or used as a substitute for medical advice, diagnosis or treatment. This site and its services do not constitute the practice of any medical, nursing or other professional healthcare advice, diagnosis or treatment. You should always talk to your healthcare provider for diagnosis and treatment, including your specific medical needs. None of the products or services offered through this website represents or warrants that any particular service or product is safe, appropriate or effective for you. Always consult with your physician or another medical professional first before implementing any of our advice, information, or suggestions. Always consult with a physician or medical professional (not us) before implementing any changes to your diet, medication, lifestyle, exercise regimen, supplement regimen, or health practices. Please only implement any and all changes after consulting with your physician and assessing your own risk. Use of this Site or its Services does not constitute a patient-healthcare provider relationship. Users should always seek the advice of a physician or other qualified healthcare provider with any questions regarding personal health or medical conditions. Patients with healthcare related questions should call or see their physician or other healthcare provider promptly, and should not disregard professional medical advice, or delay seeking it, because of the Content. Never disregard professional medical advice or delay in seeking it because of something you have read on the Site! If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. If you are in the United States and are experiencing a medical emergency, please call 911 or call for emergency medical help on the nearest telephone. Information Is No Substitute for Professional Advice This Site contains only informational and educational material and information. The content on this Site is not a substitute for the advice of your attorney, physician, medical professional, mental health professional, financial advisor, accountant, or any other professional. Testimonials The Testimonials or examples on the Site are simply that: examples. While they are all accurate and authentic, we are not making any claims that you will experience the same or better results from using the Site and/or Services. External links disclaimer The Neuroendocrine Cancer Foundation website may contain links to external websites that are not provided or maintained by or in any way affiliated with the Neuroendocrine Cancer Foundation. Please note that the Neuroendocrine Cancer Foundation does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites. The mention of any product, service, organization, activity or therapy on the Website, Social Media or Apps should not be construed as the Neuroendocrine Cancer Foundation endorsement. 2. LICENSE TO USE WEBSITE Unless otherwise stated, the Neuroendocrine Cancer Foundation and/or its licensors own the intellectual property rights in the website and material on the website. Subject to the license below, all these intellectual property rights are reserved. You may view, download for caching purposes only, and print pages or other content from the website for your own personal use, subject to the restrictions set out below and elsewhere in these terms and conditions. You must not: Republish material from this website (including republication on another website); sell, rent or sub-license material from the website; show any material from the website in public; reproduce, duplicate, copy or otherwise exploit material on this website for a commercial purpose; edit or otherwise modify any material on the website; or redistribute material from this website except for content specifically and expressly made available for redistribution. Where content is specifically made available for redistribution, it may only be redistributed within your organization. Acceptable use You must not use this website in any way that causes, or may cause, damage to the website or impairment of the availability or accessibility of the website; or in any way which is unlawful, illegal, fraudulent or harmful, or in connection with any unlawful, illegal, fraudulent or harmful purpose or activity. You must not use this website to copy, store, host, transmit, send, use, publish or distribute any material which consists of (or is linked to) any spyware, computer virus, Trojan horse, worm, keystroke logger, rootkit or other malicious computer software. You must not conduct any systematic or automated data collection activities (including without limitation scraping, data mining, data extraction and data harvesting) on or in relation to this website without the Neuroendocrine Cancer Foundation's express written consent. You must not use this website to transmit or send unsolicited commercial communications. You must not use this website for any purposes related to marketing without the Neuroendocrine Cancer Foundation's express written consent. User content In these terms and conditions, “your user content” means material (including without limitation text, images, audio material, video material and audio-visual material) that you submit to this website, for whatever purpose. You grant to the Neuroendocrine Cancer Foundation a worldwide, irrevocable, non-exclusive, royalty-free license to use, reproduce, adapt, publish, translate and distribute your user content in any existing or future media. You also grant to the Neuroendocrine Cancer Foundation the right to sub-license these rights, and the right to bring an action for infringement of these rights. Your user content must not be illegal or unlawful, must not infringe any third party's legal rights, and must not be capable of giving rise to legal action whether against you or the Neuroendocrine Cancer Foundation or a third party (in each case under any applicable law). You must not submit any user content to the website that is or has ever been the subject of any threatened or actual legal proceedings or other similar complaints. The Neuroendocrine Cancer Foundation reserves the right to edit or remove any material submitted to this website, or stored on the Neuroendocrine Cancer Foundation’s servers, or hosted or published upon this website. Notwithstanding the Neuroendocrine Cancer Foundation’s rights under these terms and conditions in relation to user content, the Neuroendocrine Cancer Foundation does not undertake to monitor the submission of such content to, or the publication of such content on, this website. No warranties This website is provided “as is” without any representations or warranties, express or implied. The Neuroendocrine Cancer Foundation makes no representations or warranties in relation to this website or the information and materials provided on this website. Without prejudice to the generality of the foregoing paragraph, the Neuroendocrine Cancer Foundation does not warrant that: this website will be constantly available, or available at all; or the information on this website is complete, true, accurate or non-misleading. The mention of any product, service, organization, activity or therapy on the Website, Social Media or Apps should not be construed as a Neuroendocrine Cancer Foundation endorsement. Nothing on this website constitutes, or is meant to constitute, advice of any kind. If you require advice in relation to any legal, financial or medical matter you should consult an appropriate professional. Limitations of liability The Neuroendocrine Cancer Foundation assumes no responsibility for any injury or damage to persons or property arising out of or related to the Content, the Website, or the Apps. The Neuroendocrine Cancer Foundation will not be liable to you (whether under the law of contract, the law of torts or otherwise) in relation to the contents of, or use of, or otherwise in connection with, this website: to the extent that the website is provided free-of-charge, for any direct loss; for any indirect, special or consequential loss; or for any business losses, loss of revenue, income, profits or anticipated savings, loss of contracts or business relationships, loss of reputation or goodwill, or loss or corruption of information or data. These limitations of liability apply even if the Neuroendocrine Cancer Foundation has been expressly advised of the potential loss. Exceptions Nothing in this website disclaimer will exclude or limit any warranty implied by law that it would be unlawful to exclude or limit; and nothing in this website disclaimer will exclude or limit the Neuroendocrine Cancer Foundation’s liability in respect of any: death or personal injury caused by the Neuroendocrine Cancer Foundation’s negligence; fraud or fraudulent misrepresentation on the part of the Neuroendocrine Cancer Foundation; or matter which it would be illegal or unlawful for the Neuroendocrine Cancer Foundation to exclude or limit, or to attempt or purport to exclude or limit, its liability. Social Media Disclaimer By accessing, viewing and/or posting content to any Neuroendocrine Cancer Foundation Social Media Site on the internet, including but not limited to our blogs, Facebook, Twitter, Instagram, YouTube, and online forums, you accept, without limitation or qualification, the following terms of use, as well as any other terms of use required by the company that owns and operates the underlying social media site (e.g.,, any terms of use required by Facebook, Twitter, etc.). If you do not agree to the terms of this Policy, you may not view of post any content to any Neuroendocrine Cancer Foundation Social Media Site on the internet. Your use of Neuroendocrine Cancer Foundation Social Media Sites is acceptance of this Policy and has the same effect as if you had actually physically signed an agreement. Rules of Conduct DO NOT transmit materials in any manner that is unlawful, disruptive, threatening, profane, abusive, harassing, embarrassing, tortuous, defamatory, obscene, libelous, or is an invasion of another’s privacy, is hateful or racially, ethnically or otherwise objectionable as solely determined by the Neuroendocrine Cancer Foundation staff. DO NOT impersonate any person or entity or falsely state or otherwise misrepresent your affiliation with a person or entity. DO NOT transmit any unsolicited or unauthorized advertising, promotional materials, or any other form of solicitation. DO NOT transmit any materials that contain any kind of virus, spyware, or malware. DO NOT violate another’s copyright or intellectual property. DO NOT post any proprietary, confidential, sensitive, or nonpublic information. NCF RESERVES THE RIGHT TO (but is not obligated) to do any of the following: Moderate all content; Remove information, language, or any communication considered offensive and/or fails to conform with these terms of use; Edit or delete any communications posted on the Site or Social Media, regardless of whether such communications violate these standards; Block users who violate these guidelines. Exceptions Nothing in this website disclaimer will exclude or limit any warranty implied by law that it would be unlawful to exclude or limit; and nothing in this website disclaimer will exclude or limit the Neuroendocrine Cancer Foundation’s liability in respect of any: death or personal injury caused by the Neuroendocrine Cancer Foundation’s negligence; fraud or fraudulent misrepresentation on the part of the Neuroendocrine Cancer Foundation; or matter which it would be illegal or unlawful for the Neuroendocrine Cancer Foundation to exclude or limit, or to attempt or purport to exclude or limit, its liability. Reasonableness By using this website, you agree that the exclusions and limitations of liability set out in this website disclaimer are reasonable. If you do not think they are reasonable, you must not use this website. Other parties You accept that, as a limited liability entity, the Neuroendocrine Cancer Foundation has an interest in limiting the personal liability of its officers and employees. You agree that you will not bring any personal claim against the Neuroendocrine Cancer Foundation's officers or employees with respect to any losses you suffer in connection with the website. You agree that the limitations of warranties and liability set out in this website disclaimer will protect the Neuroendocrine Cancer Foundation’s officers, employees, agents, subsidiaries, successors, assigns and sub-contractors as well as the Neuroendocrine Cancer Foundation. Unenforceable provisions If any provision of this website disclaimer is, or is found to be, unenforceable under applicable law, that will not affect the enforceability of the other provisions of this website disclaimer. Indemnity You hereby indemnify the Neuroendocrine Cancer Foundation and undertake to keep the Neuroendocrine Cancer Foundation indemnified against any losses, damages, costs, liabilities and expenses (including without limitation legal expenses and any amounts paid by the Neuroendocrine Cancer Foundation to a third party in settlement of a claim or dispute on the advice of the Neuroendocrine Cancer Foundation’s legal advisers) incurred or suffered by the Neuroendocrine Cancer Foundation arising out of any breach by you of any provision of these terms and conditions, or arising out of any claim that you have breached any provision of these terms and conditions. Breaches of these terms and conditions Without prejudice to the Neuroendocrine Cancer Foundation’s other rights under these terms and conditions, if you breach these terms and conditions in any way, the Neuroendocrine Cancer Foundation may take such action as the Neuroendocrine Cancer Foundation deems appropriate to deal with the breach, including suspending your access to the website, prohibiting you from accessing the website, blocking computers using your IP address from accessing the website, contacting your internet service provider to request that they block your access to the website and/or bringing court proceedings against you. Variation The Neuroendocrine Cancer Foundation may revise these terms and conditions from time-to-time. Revised terms and conditions will apply to the use of this website from the date of the publication of the revised terms and conditions on this website. Please check this page regularly to ensure you are familiar with the current version. Assignment The Neuroendocrine Cancer Foundation may transfer, sub-contract or otherwise deal with the Neuroendocrine Cancer Foundation’s rights and/or obligations under these terms and conditions without notifying you or obtaining your consent. You may not transfer, sub-contract or otherwise deal with your rights and/or obligations under these terms and conditions. Severability If a provision of these terms and conditions is determined by any court or other competent authority to be unlawful and/or unenforceable, the other provisions will continue in effect. If any unlawful and/or unenforceable provision would be lawful or enforceable if part of it were deleted, that part will be deemed to be deleted, and the rest of the provision will continue in effect. Entire agreement These terms and conditions constitute the entire agreement between you and the Neuroendocrine Cancer Foundation in relation to your use of this website, and supersede all previous agreements in respect of your use of this website. The Neuroendocrine Cancer Foundation is also known as the Learn Advocate Connect Neuroendocrine Tumor Society (LACNETS). You may contact the Neuroendocrine Cancer Foundation by email at info@neuroendocrinecancer.net . Disclaimer The information contained on the www.neuroendocrinecancer.net website is for general information purposes only. The Neuroendocrine Cancer Foundation assumes no responsibility for errors or omissions in the contents on the Service. In no event shall the Neuroendocrine Cancer Foundation) be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Neuroendocrine Cancer Foundation reserves the right to make additions, deletions, or modification to the contents on the Service at any time without prior notice. The Neuroendocrine Cancer Foundation does not warrant that the website is free of viruses or other harmful components. External links disclaimer The Neuroendocrine Cancer Foundation website may contain links to external websites that are not provided or maintained by or in any way affiliated with the Neuroendocrine Cancer Foundation. Please note that the Neuroendocrine Cancer Foundation does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites. Last updated February 17, 2025

<< Go back to the Podcast page EPISODE 38: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES PART I: Overview and Ablative Techniques Including Histotripsy Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. MEET DR. OSMAN AHMED Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY INCLUDING HISTOTRIPSY: What is liver-directed therapy? How does it work? Is this considered “surgery”? What is a surgery and what is a “procedure?” What are the types of liver-directed therapies used for neuroendocrine cancer? Which neuroendocrine cancers are they used for and when are they used? How do you decide who is a good candidate and if it will be effective? When are liver-directed therapies NOT used? Can someone who has had a Whipple undergo liver-directed therapy? What is the ablation zone? What is a heat sink effect? What is histotripsy? How does it work? When is histotripsy used (tumor grade, type of tumor - PNET/lung NET, size, number of tumor, location)? Can they be used for liver tumors even if there are tumors outside the liver? What are the limitations to histotripsy? What happens to the liver tissue after ablation? What are the results or success rates of patients being treated? Can histotripsy “cure” NET? How do you decide between the various types of liver-directed therapies? RESOURCES WATCH LACNETS Liver-Directed Therapy Videos READ "First Release #HOPE4LIVER Data Reveals 'Exciting' Potential of Histotripsy for Liver Tumours" "The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors" "HistoSonics® Publishes Results of its Pivotal #HOPE4LIVER Trials" OTHER RESOURCES The company, HistoSonics recently launched a new website – called myhistotripsy.com – to help educate patients on histotripsy and help them locate treatment sites. The website offers an overview of histotripsy and features patient stories, a form to help determine if histotripsy is right for you, and resources to find a doctor near you. Visit the Patient Website DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Want to know which NET specialists other patients see? Wondering who is on octreotide and who is on lanreotide, as well as their opinion on either? Curious to learn how many people have had the Gallium68 scan and where they got the scan done? The Neuroendocrine Cancer Foundation launched a private Facebook group exclusively for NET patients and caregivers to have a safe space to ask questions, share helpful information and seek support from one another. Please note: This private group is for NET patients and caregivers only. Click here to join the Facebook Group

<< Go back to the Podcast page EPISODE 45: SPOTLIGHT ON MEDICAL ONCOLOGY Download a Transcript of this Episode >>> ABOUT THIS EPISODE One of the key aspects of one’s neuroendocrine cancer care is building your medical team, which typically includes a medical oncologist. In this episode, Medical Oncologist Dr. Sandy Kotiah from Mercy Medical Center in Baltimore expounds on the role of a medical oncologist. She sheds light on the first appointment, communication, and care coordination. MEET SANDY D. KOTIAH, MD Sandy D. Kotiah, M.D., a Board Certified medical oncologist, serves as the Director of The Neuroendocrine Tumor Center at Mercy and is a member of Medical Oncology and Hematology at Mercy in Baltimore, Maryland. Dr. Kotiah leads a multidisciplinary team of specialty doctors focused on providing some of the best treatment options for rare neuroendocrine diseases. Dr. Kotiah’s compassionate and caring nature as well as her exceptional clinical knowledge and dedication to searching for answers to complicated cancer diagnoses makes her a sought-after Medical Oncologist and Hematologist in the Baltimore region . TOP TEN QUESTIONS: What is your role in the neuroendocrine cancer world? What is your role with your medical team? What is a medical oncologist? What training is involved? Is a medical oncologist the same thing as a hematologist oncologist? What’s the difference between a medical oncologist & surgical oncologist (& radiation oncologist)? What is a NET expert and how does someone become a NET expert? When I’m looking for a NET expert, what type of doctor am I looking for? How do I know if I’m with a “NET expert”? If I call a medical institution, will I automatically get assigned to a “NET expert?” If someone tells me they are a “NET expert,” does that mean that person is a NET expert? What can I expect on my first appointment? What type of information do you try to communicate with your patients during the first appointment? Newly diagnosed patients often come to their first appointment feeling scared and overwhelmed. They wonder “how long do I have,” worry about how fast the cancer is growing, and are unsure of what to tell their family and friends. How do you address these concerns? What questions should I be asking my oncologist? When/how often should I see my medical oncologist? Who goes over my scan results with me? When does that happen/How soon after a scan should I expect results? Who communicates the tumor board discussions? How is care coordinated with other providers on my team within the same institution? How is care coordinated with other providers from different institutions (i.e. with a local oncologist and a NET expert)? What happens if someone wants a second opinion? How do you feel about second opinions? How do I navigate or work through a situation in which there are differing opinions between doctors? If I have a question, concern, or symptoms, who do I communicate with and what’s the best way to communicate? What if we “run out of time” during an appointment? What if it’s a question or concern I’m shy about communicating? Some people struggle with trust because of past experiences with providers who might have ignored or minimized their symptoms. What advice do you have to help build trust with my doctor? What would you say is my responsibility as a patient and your responsibility as the oncologist? If there is one thing you would like all people living with neuroendocrine cancer to know, what would it be? DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Back Neuroendocrine Carcinomas (NECs) & Grade 3 Neuroendocrine Tumors (NETs) Grade 3 NET Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors CHM-2101 CAR-T cell for GI Cancers COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs DAREON™-7: DLL-3 For Advanced Neuroendocrine Cancers IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Olaparib in GEP-NETs Lu-177 DOTATATE + Sunitinib in PNETs SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029) STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) SWOG S2104: Adjuvant CAPTEM for High Risk pNET Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms Neuroendocrine Carcinoma (NEC) 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors DAREON®-NEC-1: Obrixtamig Plus Chemotherapy vs Standard Chemotherapy in Advanced epNEC DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms ZL-1310 (DLL3-targeted ADC) in DLL3+ Tumors

<< Go back to the Podcast page EPISODE 41: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community. MEET DR. GUILLAUME PEGNA Dr. Pegna is a medical oncologist specializing in caring for adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors, including pheochromocytomas, paragangliomas and adrenocortical carcinomas, as well as other gastrointestinal cancers. Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient and supporting them through their treatment journeys. TOP 10 ABSTRACTS AT THE 2024 NANETS SYMPOSIUM: View the abstracts in the NANETS 2024 Symposium Abstract Guide Improving our understanding of PRRT/optimizing therapy: Mosalem et al. Abstract C-19 Safety of Lutetium-177 DOTATATE Treatment in Patients with Advanced Neuroendocrine Tumors and Extensive/ Innumerable Bone Metastases Singh and Iyer et al. Abstract O-13 Prevalence of CHIP Mutations in patients with Neuroendocrine Tumors and Role in Predicting Hematologic Toxicity to PRRT and Chemotherapy Fidelman et al. Abstract C-27 A Pilot Study of Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases Alpha PRRT is Coming Wahl et al. Abstract C-37 Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs) Strosberg et al. Abstract C-16 Targeted Alpha Therapy with 212Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors Halperin et al. Abstract C-17 ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: Phase 1b safety/efficacy Novel Treatments/Treatment Combinations Chauhan et al. Abstract C-5 Once-daily Oral Paltusotine in the Treatment of Patients With Carcinoid Syndrome: Results From a Phase 2, Randomized, Parallel-Group Study D’Souza, Soulen et al. Abstract C-29 Initial Outcomes of Integrating Yttrium-90 Radioembolization with Capecitabine-Temozolomide for Grade 3 Liver-Dominant Metastatic Neuroendocrine Tumors Improving Our Understanding of NETs: Basic, Translational, and Epidemiologic Studies of NETs Liu and Yao: Abstract B-1 Development of innovative in vitro and in vivo patient[1]derived cancer models for translational studies in G1/G2 gastroenteropancreatic neuroendocrine tumors Estrada and Bergsland et al. Abstract O-2 Characterization of early-onset gastroenteropancreatic neuroendocrine neoplasms at UCSF Chauhan, A., Chan, K., Halfdanarson, T. R., Bellizzi, A. M., Rindi, G., O'Toole, D., Ge, P. S., Jain, D., Dasari, A., Anaya, D. A., Bergsland, E., Mittra, E., Wei, A. C., Hope, T. A., Kendi, A. T., Thomas, S. M., Flem, S., Brierley, J., Asare, E. A., Washington, K., … Shi, C. (2024). Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors . CA: a cancer journal for clinicians , 74 (4), 359–367. https://doi.org/10.3322/caac.21840 ABOUT NANETS The North American Neuroendocrine Tumor Society (NANETS) provides NET medical educational programming designed exclusively for medical professionals. While our Podcast only features 10 presentations from the November 21-23, 2024 NANETS Symposium, there are many more noteworthy abstracts found (or listed) here: NANETS Abstract Library 2024 NANETS Abstracts Booklet While NANETS does not provide direct patient education, patients may help further NET education of medical professionals by sharing the organization's educational meetings and NET guidelines with their providers. RESOURCES WATCH https://www.youtube.com/watch?v=oqk0tk7W-IM Dr. Will Pegna Discusses Highlights from the 2024 NANETS Symposium LISTEN Top 10 Highlights of the 2023 NANETS Symposium Top 10 Highlights of the 2022 NANETS Symposium DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Learn more about the NET experts presenting on various topics during the 2024 LACNETS Neuroendocrine Tumor Patient Conference. 2025 Conference Speakers << Go back to the 2025 Annual Conference Page Overview of Neuroendocrine Cancer What is Neuroendocrine Cancer? Bhavana Konda, MD, MPH Medical Oncologist, Ohio State University Comprehensive Cancer Center (OSUCCC) Dr. Bhavana Konda is a Medical Oncologist with expertise in neuroendocrine tumors and endocrine-related cancers. She leads the Neuroendocrine Tumor and Endocrine Medical Oncology Section at the Ohio State University Comprehensive Cancer Center. Her research is dedicated to advancing treatment options to patients with these rare cancers through innovative clinical trials. Understanding Matters About Biomarkers & Blood Tests Thorvardur Halfdanarson, MD Medical Oncologist, Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson is President Emeritus of the North American Neuroendocrine Tumor Society (NANETS) as well. What Matters About Scans Nadine Mallak, MD Radiologist & Nuclear Medicine, Oregon Health & Science University Nadine Mallak, M.D. is a double boarded Associate Professor of Diagnostic Radiology at OHSU, in the divisions of Body Imaging, and Molecular Imaging & Therapy. She received her M.D. degree from Saint Joseph University Medical School in Beirut, Lebanon, followed by a Diagnostic Radiology residency at Hotel Dieu de France, Beirut. Subsequently, she finished fellowships in Neuroradiology and Abdominal Imaging, and a residency in Nuclear Medicine at the University of Iowa Hospitals and Clinics. Dr. Mallak is the clinical director of the PET/MRI program at OHSU. The scope of her clinical practice encompasses all aspects of molecular imaging and therapy, in addition to abdominal and pelvic imaging with modalities including ultrasound, CT, and MRI. Her research interests focus on molecular and hybrid imaging, particularly for prostate cancer, neuroendocrine tumors and pheochromocytoma/paraganglioma. In addition to her research projects, she’s passionate about education. She was voted by the radiology residents "outstanding teacher of the year" for the year 2019-2020, and by the graduating senior residents “outstanding board reviewer” for the year 2021-2022 In her free time, she enjoys painting, mostly with acrylic and watercolors, reading, hiking, and exploring the gorgeous nature in the Pacific Northwest. What Matters About Symptom Management Vineeth Sukrithan, MD Medical Oncologist, Ohio State University Comprehensive Cancer Center (OSUCCC) Dr. Vineeth Sukrithan is a medical oncologist who specializes in the study and treatment of neuroendocrine cancer, thyroid cancer and adrenocortical cancer. He utilizes traditional chemotherapy, molecularly targeted oral medications, novel immunotherapy and peptide-receptor radiotherapies in the treatment of these unique cancers. As a comprehensive cancer center, the OSUCCC – James has unrivaled experience and expertise in the treatment of neuroendocrine, thyroid and adrenal tumors. Their world-renowned faculty are leaders in the study and treatments of these rare cancers, and as such, they are able to provide their patients with options beyond standard therapies that may not be available anywhere else. The strong focus on translational research at The James means that the treatment breakthroughs of tomorrow are being discovered in their laboratories today. Dr. Sukrithan is part of a tight-knit team of surgical oncologists, radiation oncologists and interventional radiologists who work together to provide cutting-edge care for our patients with neuroendocrine tumors. In addition to his clinical work, Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC – James and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer. Dr. Sukrithan also serves as an assistant professor in the Division of Medical Oncology at The Ohio State University and has completed postdoctoral fellowships in clinical research at Johns Hopkins University. His research has been published in numerous peer-reviewed journals, including Cancer Research, American Journal of Clinical Oncology and Clinical Lung Cancer. As every individual’s cancer is molecularly unique in countless ways, Dr. Sukrithan believes in tailoring therapies to the individual with the precision made available through cutting-edge scientific research. He feels it is a privilege to make a difference in the lives of patients as we work together to achieve a cancer-free world. Surgery & Local Regional Therapies What Matters About Liver Surgery Julie Hallet, MD, MSc., FRCSC Surgical Oncologist, Sunnybrook Health Sciences Center Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. What Matters About Liver-Directed Therapy Alejandro Gabutti, MD Interventional Radiologist, National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ) University Hospital and National Reference Center for Liver Diseases Dr. Alejandro Gabutti, born in southern Mexico and moved to Mexico City for medical school. He received his medical degree from the UNAM (National University of Mexico) in 2008. After a year working as a general doctor in the mountain region of Chiapas, Mexico, he decided to continue his medical education as a Radiologist. By the year 2006 Alejandro was accepted in the INCMNSZ and completed a 4-year radiology program. Since the very beginning during his radiology training Alejandro showed a special interest in the interventional radiology procedures. He successfully completed a two-year interventional radiology fellowship at the INCMNSZ. At the conclusion of his fellowship, Alejandro was hired as part of the INCMNSZ radiology staff. In 2019 Dr. Gabutti moved to Milan Italy and completed a 1-year internship at the Istituto Nazionale dei Tumori, with special emphasis in oncological liver directed therapies. By his return to Mexico, Alejandro continues working as an Interventional Radiologist at the INCMSNZ, became the Interventional Radiology program professor (UNAM) and keeps working to improve liver malignancies imaging and treatments. Expert Panel: What Matters Most in Making Decisions About Surgery & Local Regional Therapies Daneng Li, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. Callisia Clarke, MD Surgical Oncologist, Medical College of Wisconsin Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Osman Ahmed, MD Interventional Radiologist, University of Chicago Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. William C. Chen, MD Radiation Oncologist, University of California San Francisco Dr. William C. Chen is a radiation oncologist and translational researcher. Dr. Chen received his undergraduate degree from Johns Hopkins University and completed medical school at the University of California, San Francisco. He completed his internal medicine preliminary internship at Kaiser San Francisco, followed by a residency in Radiation Oncology at UCSF. He is a Chan Zuckerburg Biohub Physician Scientist Fellow and a Helen Diller Family Cancer Center Physician Scientist Program in Clinical Oncology (PSPCO) Fellow. His research focuses on biomarker development, informatics, and clinical trial development with a focus on meningiomas and other malignancies of the central nervous system and beyond. Medical Management & Sequencing Treatments What Matters About Systemic Treatments Jennifer Chan, MD, MPH Medical Oncologist, Dana-Farber Cancer Institute Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. Dr. Chan focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. She is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. Dr. Chan has been principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and has been involved in studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors. She is a past chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS) and President of NANETS. Dr. Chan serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel. She is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute and the Board of Directors of NANETS. What Matters About PRRT: What is PRRT & How Does It Work? Cecilia Carreras Velázquez Nuclear Medicine, Hospital Ángeles Lomas Dr. Cecilia Carreras Velázquez is a board-certified specialist in Nuclear Medicine and Molecular Imaging, based in Mexico City. Graduated with honors from Centro Médico ABC (UNAM) in 2010 and completed a fellowship in Molecular Imaging in 2011. From 2012 to 2024, she served as Head of the Nuclear Medicine and PET/CT Department at Hospital Angeles Lomas, where she led the integration of advanced technology and the expansion of radionuclide-based diagnostic and therapeutic services. Pioneer in Mexico in implementing Lutetium-177 therapy for patients with Neuroendocrine Tumors and metastatic prostate cancer. In June 2024, Dr. Carreras assumed the position of Medical Director of Nuclear Medicine at the National Center for Radiology and Imaging within the Angeles Health System Hospitals in Mexico. Dr. Carreras has international experience, having collaborated with the research team at PET-Zentrum of Zentralklinik Bad Berka in Germany, focused on radionuclide therapies for neuroendocrine tumors. Since 2020, she has been a member of the Patient Safety and Quality Committee at Hospital Angeles Lomas, and in 2022, she was appointed Mexico Ambassador for the Oncidium Foundation, advocating for innovations in cancer treatment through nuclear medicine. For over a decade, she has actively participated in educational initiatives, specialty dissemination efforts, and patient-focused forums to enhance understanding and access to nuclear medicine advancements. What Matters About PRRT: Preventing and Managing Toxicities & Latest Advances Aman Chauhan, MD Medical Oncologist, University of Miami Health System Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. What Matters About Clinical Trials Pamela Kunz, MD Medical Oncologist, Yale Medicine Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including past President of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. Dr. Kunz was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021. Dr. Kunz was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity and received the 2024 'Distinguished Mentor Award' by the North American Neuroendocrine Tumor Society. X @PamelaKunzMD Expert Panel: What Matters Most in Making Decisions About Systemic Therapies & Sequencing Treatments J. Randolph Hecht, MD Medical Oncologist, UCLA Health Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. Alexandra Gangi, MD Division Director of Surgical Oncology, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the Division Director of Surgical Oncology and Director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. Erik Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training at Stony Brook University and subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty at Stanford for many years before moving to Oregon Health & Science University in 2018. Dr. Mittra is involved in all aspects of Nuclear Medicine but theranostics for oncology is of particular interest. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is a prior Medical Director of the Healing NET Foundation (HNF). David B. Zhen, MD Medical Oncologist, Fred Hutch Cancer Center Dr. David Zhen is a medical oncologist who specializes in treating patients with gastrointestinal cancers. His research centers around the development of clinical trials evaluating new therapies and combination approaches for the treatment of patients with gastrointestinal cancers, particularly pancreatic and gastroesophageal cancers. He is also conducting research to understand the interactions of the immune system in gastrointestinal cancers and how this can be manipulated to improve upon the response to immunotherapy drugs called checkpoint inhibitors, which block a braking system that cancers use to tamp down the immune response. Moderators: MARY DONLEVY NCF Board member and NET Patient Advocate Mary Donlevy joined the NCF Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time. Andrew Hendifar, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. << Go back to the 2025 Annual Conference Page

<< Back Lung/Bronchial NETs PRRT/RLT Trials 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE vs Everolimus in Lung NETs Immunotherapies DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms Targeted Therapies Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

<< Go back to the Podcast page EPISODE 30: BONE & BRAIN METASTASES IN NEUROENDOCRINE CANCER Download a Transcript of this Episode >> ABOUT THIS EPISODE When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases. MEET DR. ROBERT RAMIREZ, DO, FACP Dr. Robert Ramirez is a medical oncologist specializing in the treatment of thoracic and neuroendocrine malignancies and an Associate Professor of Medicine at Vanderbilt University Medical Center in Nashville, TN. He earned his medical degree from the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine. He completed an internal medicine residency at Cooper University Hospital in Camden, New Jersey. He then completed a hematology and medical oncology fellowship at the University of Tennessee Health Sciences Center in Memphis, Tennessee and served as chief fellow. He is a Fellow of the American College of Physicians, and a member of American Society of Clinical Oncology, the International Association for the Study of Lung Cancer (IASLC), and the North American Neuroendocrine Tumor Society (NANETS). He serves on the Board of Directors for NANETS as well as the Scientific Review and Research Committee. His clinical and research interests include neuroendocrine tumors (NETs) and lung cancer. He has a specific interest in NETs of the lung ranging from diffuse idiopathic pulmonary neuroendocrine tumor cell hyperplasia (DIPNECH) and carcinoid tumors to small cell lung cancer and other high-grade neuroendocrine carcinomas. He is active in clinical trial design including investigator-initiated trials. He enjoys teaching residents and fellows and has multiple publications and given many lectures for the scientific community on the topics of NETs and lung cancers. TOP TEN QUESTIONS Bone mets: 1. When and how often do NETs spread to the bones? 2. Where in the bones are tumors? What does it mean when NETs spread to the bones? How does this compare to other cancers? 3. How are bone spots found and monitored? Should they be biopsied? 4. What is the treatment for bone mets? Should I have radiation? Would radiation limit my ability to get PRRT? 5. Should I be on bone strengthening medication? Am I at higher risk for fractures (or breaking my bones) if I have NETs in the bones? 6. Do bone mets respond to PRRT? 7. Does having bone mets put me at a higher risk of MDS? Brain mets: 8. When and how often do NETs spread to the brain? Do all types of NETs have the potential to spread to the brain? 9. How are brain mets found and monitored? When should I suspect this? 10. How are brain mets treated? What does having brain mets mean for my life? *Bonus: What final words of hope do you have for the neuroendocrine cancer community? RESOURCES WATCH https://www.youtube.com/watch?v=eC5OGO6VvEE LISTEN LACNETS Lung NET Resources DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Join NCF for Feb2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=nrbsUI54nEM Some Topics Covered: Neuroendocrine, NET, clinical trials, PRRT, RLT, neoadjuvant trials, adjuvant trials, metastatic NET, symptom control Download the slides >>> ABOUT Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. The presentation will focus on current NET clinical trials. For information on NEC clinical trials, go to our high grade resources page: https://www.ncf.net/high-grade-nen-resources . ABOUT DR. HELOISA P. SOARES Medical Oncologist Huntsman Cancer Institute (HCI) University of Utah Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79 RESOURCES https://www.youtube.com/watch?v=cmKEuKfOcGw The Latest on Immunotherapy for Neuroendocrine Cancer with Dr. Aman Chauhan (Dec 2025) Additional Clinical Trials Resources: https://www.ncf.net/clinical-trials/additional-resources https://www.youtube.com/watch?v=CXW71vedhIw "Navigating Clinical Trials: Expectations vs. Realities" with Taymeyah Al-Toubah • Aug 2023 https://www.youtube.com/watch?v=Kf3p_j5tFVU Clinical Trials: Why, What & How • Josh Mailman • 2023 Patient Education Conference THANKS TO OUR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

In Loving Memory Giovanna Joyce Imbesi Our founder, hero & inspiration to live life fully… Giovanna Joyce Imbesi, LACNETS founder, was a patient advocate, pianist, and composer based in Los Angeles. She lived fully with neuroendocrine cancer for 14 years and served as a model of compassion, love and kindness. In 2005, after several years of misdiagnosis, Giovanna was diagnosed with metastatic small bowel neuroendocrine cancer. She understood that those with a rare cancer may feel isolated, and sharing similar experiences may lessen the fear of the unknown and offer comfort. It became her mission to help others in the NET community. Her vision was to create a community for a healing exchange of educational resources and emotional support for all affected by neuroendocrine cancer. Against all odds, Giovanna went on to receive an MBA from UCLA Anderson School of Management with the sole intent of launching LACNETS. In 2012, she founded the non-profit GeneratePossibility and the Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS) program. Giovanna's physician, Dr. Edward Wolin, was the inaugural speaker for the first LACNETS' patient education meeting. Through LACNETS, Giovanna's aspiration was to create a more "NET-fluent" world. She wanted to change the narrative from associating NET with famous people who die from the disease to raising awareness of the more than 180,000 people who live with the disease. Giovanna wrote, "Each one of us has the ability to help change those numbers in our own community. There are more opportunities to share more about NET and add one more person to the extended global family of NET awareness." Giovanna helped create tools, such as NET VITALS, to improve communication between patients and physicians. She believed that increased awareness equates to more research, which leads to improved treatments and patient outcomes. Giovanna received the 2016 Monica Warner Advocacy Award, as well as the 2019 Cedars-Sinai Patient Leadership Award , for her inspiring work in patient advocacy. Giovanna Joyce Imbesi passed away peacefully on November 24th, 2019. On her last day, Giovanna said with great pride that her greatest legacy was LACNETS. She felt blessed by this community. Giovanna often said, "Aging is a privilege." She celebrated life and connectedness. She believed in practicing gratitude, even appreciating the difficult times. She was grateful for the thousands of neuroendocrine tumor physicians, researchers and healthcare providers who work on the behalf of NET patients every day. The Neuroendocrine Cancer Foundation works daily to honor Giovanna's vision by serving the NET community she established and helping others to live life richly and fully with NET like she did. Participate in the Vision Watch the tribute video honoring Giovanna Joyce Imbesi by Rich Tamayo, Emmy Winning Video Producer & a friend of LACNETS GENERATE POSSIBILITY For Giovanna, music was medicine. Her musical compositions can be heard on "Short Stories - piano music for healing, meditation & relaxation" recorded while in recovery from neuroendocrine cancer surgery. These pieces were inspired by her belief in the healing power of music as a vital element of our well-being. She frequently contributed music to NET causes. A frequent speaker on living with neuroendocrine cancer and the healing power of music, Giovanna was featured as one of six leaders in Integrative Cancer Care at the 2018 Symington Public Forum at Commonweal. We hope that Giovanna's song and her own words, "Give Me Peace," bring some comfort and peace. I’ll always be grateful for Giovanna and her work through LACNETS (now Neuroendocrine Cancer Foundation). The information I learned and connections I made through the educational meetings changed the course of my medical care and helped me to get back to a place where I could enjoy life. — Tom, NET Patient

<< Go back to the Podcast page EPISODE 3: SURGERY FOR NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE To cut or not to cut? A crossroad many neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope answers the top 10 surgery questions for NETs. MEET DR. GAGANDEEP SINGH Gagandeep Singh, M.D., is an internationally recognized liver and pancreas surgeon. He is head of hepatobiliary and pancreatic surgery service City of Hope, a National Cancer Institute-designated comprehensive cancer center. He is also the surgical director of the Neuroendocrine Tumor Program and is the lead for the gastrointestinal disease team. He started his faculty academic career at Keck School of Medicine of USC in Los Angeles. From there, he was appointed as director of the Liver and Pancreas Center at the John Wayne Cancer Institute, Santa Monica, California, where he also served as chair of the Cancer Committee and vice president for Fellowship Education. In 2010, City of Hope asked Dr. Singh to spearhead the liver and pancreatic cancer program. He was appointed clinical professor of surgery and as the new chief of the Division of Surgical Oncology (2011 to 2019) and hoisted the program to national recognition. He has an extensive referral base that reflects peer recognition of his clinical acumen and surgical expertise and is listed in “America’s Top Surgeons,” “Best Doctors of America,” “Super Doctors” and “Top Doctors of America.” Prior to his tenure in the Unites States, he earned is his medical degree from the Mahatma Gandhi Institute of Medical Sciences in India, and then trained at some of the finest cancer centers and hepatobiliary institutes around the world. These international institutions include: Tata Memorial Hospital and Cancer Center (Bombay, India), René Descartes University - Hôpital Cochin (Paris, France) and the Royal Liverpool University Hospital (England). In the U.S., these institutes include: Marion Bessin Liver Center at the Albert Einstein College of Medicine (New York), Maricopa Medical Center (Phoenix) and the University of Iowa Hospitals & Clinics (Iowa City). Dr. Singh is a board-certified surgeon, a diplomate of the American Board of Surgery and a fellow of the American College of Surgeons. He is a member of some of the top elite surgical societies and has served as invited speaker/chair at several national and international conferences. He is also a panel member of the National Comprehensive Cancer Network for Hepatobiliary Cancers, that lays down the guidelines for the standard of care for these cancers; providing direction to both patients and physicians across the U.S. and the rest of the world. Dr. Singh has a very thoughtful, effective and yet forceful approach to beating cancer, in a systematic fashion working with an outstanding multidisciplinary team. Dynamic and compassionate, he is a skilled and an accomplished surgeon. He has extensive experience in liver and pancreatic diseases and other gastrointestinal cancers. His work is very well published with numerous publications in prestigious journals. His publications encompass complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions following difficult pancreatic surgery for pancreatic cancer, and advanced robotic surgery. Currently, his group is advancing the scope and providing leading-edge surgery for complex liver and pancreatic operations using minimally invasive surgery techniques with the 3D high-definition da Vinci robotic surgical systems. His work in robotic surgery has been presented on the national podium at the Society of Surgical Oncology, Americas Hepato-Pancreato-Biliary Association, Society of Laparoscopic & Robotic Surgeons and other national meetings. An innovator at heart, Dr. Singh is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborative endeavors with engineers from California Institute of Technology (Caltech) & Harvey Mudd College. He has several invention disclosures and patents. In addition to a large clinical practice, Dr. Singh is passionately advancing leading-edge translational research. He collaborates with City of Hope’s molecular biologists, X-ray crystallographers, structural chemists and superresolution scientists. A visionary clinician, he is developing novel targeted molecules for neuroendocrine tumors, pancreatic cancers and metastatic colon and rectal cancers. He believes early detection is critical and is authenticating an early detection blood test for pancreatic cancers and colorectal cancers. ABOUT THIS EPISODE 1. Should all NET patients have surgery? How do I know if I’m a candidate for surgery? If 1 surgeon says I’m not, would another surgeon say something different? 2. How much control would a patient have regarding the approach and extent of surgery? 3. How do you control for carcinoid crisis during surgery? 4. Should all NET patients have their gallbladder removed? If mine wasn’t removed in my initial surgery, would you recommend going back to have it taken out? 5. If there are already liver mets, would you recommend having surgery? If so, how much should be taken out? Is there a role for taking out the primary tumor when there are liver mets? 6. Is there a role for surgery if there are bone mets? 7. What is the role of liver transplantation? 8. What are the risks of scar tissue from multiple surgeries? What can be done about it? (how many surgeries can a body handle?) 9. What is the role of adjuvant therapy for net? (Please also explain what adjuvant therapy is.) 10. What treatment or other development in this field are you most excited about? (What hope might you offer to those living with NET or their loved ones?) DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANKS TO OUR SPONSORS